Press Releases

Date Title  
Toggle Summary Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018
— Late-Breaking Oral Presentations on AR101 Phase 3 PALISADE Results in Peanut-Allergic Children and Adults and on European Study of Psychosocial Impact of Peanut Allergy — BRISBANE, Calif. --(BUSINESS WIRE)--May 15, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
Toggle Summary Aimmune Therapeutics to Participate in Four Upcoming Investor Conferences in May and June
BRISBANE, Calif. --(BUSINESS WIRE)--May 9, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor
Toggle Summary Aimmune Therapeutics Announces First Quarter 2018 Financial Results
BRISBANE, Calif. --(BUSINESS WIRE)--May 8, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the first quarter 2018. As of March 31, 2018 , cash, cash equivalents and
Toggle Summary Aimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
Company began 2018 with approximately $182 Million in cash and investments Pro-forma year-end 2017 cash and investments of approximately $372 Million , including net proceeds from the recently completed public offering Announced over-enrollment in the ARTEMIS Phase 3 trial Additional AR101 clinical
Toggle Summary Aimmune Therapeutics to Participate in Four Investor Conferences in March
BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 7, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor
Toggle Summary Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO
— Late-Breaking Oral Presentation by Dr. Stacie Jones — — PALISADE Results Expected to Provide Core Element of BLA Submission by Year-End 2018 — BRISBANE, Calif. & ORLANDO, Fla. --(BUSINESS WIRE)--Mar. 4, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing
Toggle Summary Aimmune Therapeutics Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 2, 2018-- Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the underwriters of its previously announced underwritten public offering of 5,500,000
Toggle Summary Aimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results on Sunday, March 4, at the AAAAI-WAO Joint Congress in Orlando
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 27, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Analyst and Investor Event on the evening of March 4, 2018 , at the joint
Toggle Summary Aimmune Therapeutics Announces Closing of Public Offering of Common Stock
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 26, 2018-- Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the completion of its previously announced underwritten public offering of 5,500,000
Toggle Summary Aimmune Therapeutics Announces Pricing of Public Offering of Common Stock
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 21, 2018-- Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at